- Home
- NCPL vs OVID Comparison
NCPL vs OVID Comparison
Compare NCPL & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- OVID
- Stock Information
- Founded
- NCPL 1984
- OVID 2014
- Country
- NCPL United States
- OVID United States
- Employees
- NCPL N/A
- OVID N/A
- Industry
- NCPL Investment Managers
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- OVID Health Care
- Exchange
- NCPL Nasdaq
- OVID Nasdaq
- Market Cap
- NCPL 19.3M
- OVID 20.6M
- IPO Year
- NCPL N/A
- OVID 2017
- Fundamental
- Price
- NCPL $3.33
- OVID $0.56
- Analyst Decision
- NCPL
- OVID Strong Buy
- Analyst Count
- NCPL 0
- OVID 4
- Target Price
- NCPL N/A
- OVID $3.13
- AVG Volume (30 Days)
- NCPL 1.1M
- OVID 2.8M
- Earning Date
- NCPL 09-15-2025
- OVID 08-12-2025
- Dividend Yield
- NCPL N/A
- OVID N/A
- EPS Growth
- NCPL N/A
- OVID N/A
- EPS
- NCPL N/A
- OVID N/A
- Revenue
- NCPL $812,612.00
- OVID $548,000.00
- Revenue This Year
- NCPL N/A
- OVID N/A
- Revenue Next Year
- NCPL $101.16
- OVID $5.32
- P/E Ratio
- NCPL N/A
- OVID N/A
- Revenue Growth
- NCPL N/A
- OVID 15.61
- 52 Week Low
- NCPL $1.41
- OVID $0.24
- 52 Week High
- NCPL $11.90
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- NCPL 38.02
- OVID 72.15
- Support Level
- NCPL $2.85
- OVID $0.30
- Resistance Level
- NCPL $5.14
- OVID $0.61
- Average True Range (ATR)
- NCPL 1.30
- OVID 0.05
- MACD
- NCPL -0.57
- OVID 0.01
- Stochastic Oscillator
- NCPL 2.80
- OVID 67.58
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.